San Francisco, 05 March 2030: The Report Viral Vector Market Size, Share & Trends Analysis Report By Vector Type (Adeno-associated Virus (AAV), Adenovirus, Lentivirus, Retrovirus, Others), By Application, By End-user, By Region, And Segment Forecasts, 2023 - 2030

The global viral vector market size is expected to reach USD 7.35 billion by 2030, registering a CAGR of 11.5% from 2023 to 2030, according to a new report by Grand View Research, Inc. Key markets driving factors include the increasing demand for gene therapy, advancements within the viral vector technology space, and growing investment favoring gene therapy and vaccine research and developments. In addition, initiatives are taken by the existing players to increase the capacity production for viral vectors which will supplement the upcoming demand. For instance, in August 2022, Thermo Fisher Scientific inaugurated a new 300,000-square-foot viral vector manufacturing facility in Massachusetts. By introducing the facility, now the company houses six viral clinical and commercial sites in the U.S. and Europe.

Contract research and manufacturing organizations continue to fuel the viral vector industry through innovations and capacity expansion to support the preclinical and overall manufacturing activities. For instance, in 2022, Genezen, a contract development and manufacturing firm specializing in lentiviral and retroviral vector manufacturing completed the construction of its early-phase clinical manufacturing facility within Indiana. Moreover, the firm highlights that the following expansion comes under its master plan for a 75,000-square-foot lentiviral and retroviral process development and cGMP production unit. Furthermore, the favorable investment space for expansionary activities pertinent to viral vectors will continue to aid market growth. For example,  Vector BioMed, a Maryland-based biomanufacturing firm was launched in January 2023 to fill the growing gap for lentiviruses as a tool for genetic medicines. The firm raised $15 million in the first round primarily led by Viking Global Investors and Casdin Capital and will transform the industry by utilizing algorithm-optimized lentiviral vectors, allowing the clients and partners to quickly move from clinical trials to commercialization.

Furthermore, the pandemic remitted a mixed impact on the market. Due to familiarity with viral vector technology in vaccines, biotechnology firms, and pharmaceutical giants were quick to respond to the social need for a COVID-19 vaccine, primarily to reduce the mortality risk of the disease. For instance, on February 2021, Janssen COVID-19 Vector viral-based vaccine by Johnson and Johnson received a EUA to prevent COVID-19 in individuals who are 18 years or older. However, the pandemic also resulted in various operational and fiscal troubles for pharmaceutical companies. Owing to various supply chain disruptions and a highly complex viral vector manufacturing line, the market faced challenges at the onset of the pandemic.

Request sample report of Viral Vector Market@ https://www.grandviewresearch.com/industry-analysis/viral-vector-market-report/request/rs1

The increasing prevalence of target diseases and genetic disorders along with technological advancements in digital diagnostics is expected to support the market growth for viral vectors. Furthermore, increasing the effectiveness of viral vectors in gene therapy delivery is contributing to market growth. The COVID-19 pandemic curated a positive impact on the global market. Owing to the high mortality rate of the COVID-19 virus, pharmaceutical, and biotechnology companies were rushed to start the research and simultaneous manufacturing of Sars-Cov-2 specific vaccines. Viral vector technology has been an established and trustable source for vaccine development. For instance, Oxford-AstraZeneca COVID-19 vaccine was made from the adenovirus vector from the already made MERS vaccine, which was clinically tested before. Thereby, the familiarity with the adenoviral properties of the vaccine allowed for a faster commercialization process, allowing billions of people to benefit from it. As per AstraZeneca, in November 2021 , nearly two billion doses of the vaccine were supplied to 185 countries, marking it as the highest geographical coverage COVID-19 vaccine. However, the pandemic also disrupted supply chains of critical raw materials which led to manufacturing challenges of viral vector therapies and other biologics. Additionally, the clinical trials were delayed which curated a longer commercialization time for various drugs and therapies dependent on viral vectors.

Viral Vector Market Report Highlights

• By vector type, the adeno-associated virus (AAV) segment held the highest share of 48% in 2022. It is due to a high degree of safety and efficacy remitted by the AAV while maintaining specificity to target cells in the body
• Cell and gene therapy segment accounted for the dominant share of 65% in the application segment for the year 2022. The dominant share is attributed to the growing gene disorder and other forms of malignancies. Moreover, high regulatory support provides a strong impetus to the segment
• By end-user, pharmaceutical and biotechnology segment held a massive share of 53% in 2022 due to the easy and larger access to public and private funds while containing high operational efficiency for complex trials and manufacturing allowing the segment to hold a dominant share
• North America took a dominant share of 48.31% share in the year 2022. It was owing to strong support from investors, while the region also garners superior healthcare coverage platforms which further necessitates a higher disease-prone patient pool

The rising prevalence of genetic disorders and contagious diseases is anticipated to boost the demand for viral vectors. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, around 38.4 million people had HIV in 2021, and at the end of 2021, 28.7 million people had accessed antiretroviral treatment. This is fueling market growth. Furthermore, government initiatives such as direct growing demand for innovative clinical therapies, funding for viral vector manufacturing, and an increasing focus on the emerging area of medicine for genetic disorders, which has helped by transforming techniques, are driving market expansion.

Increasing awareness about gene therapy coupled with the advancements in genome sequencing and a greater understanding of DNA sequences among populations for research are important factors fueling the market. The use of viral vectors in gene therapy has become a highly prospective and fast-emerging technology in recent years. Despite the difficulties previously, the widespread acceptance of viral vector therapies-many of which are in advanced stages of clinical trials-has significantly increased the amount of research in this area of gene therapy. Important vectors currently being researched and employed in clinical trials are retroviral, adenoviral, adeno-associated viral, and lentiviral based. For example, as per National Center for Biotechnology Information 2022, 137 adeno-associated viral based therapy was in clinical stages. Moreover, predominant clinical trials were in the early stages, however, around 7.7% have reached phase III.